ONCO
HEALTHCAREOnconetix Inc
AI Insight
What's Moving ONCO Today?
No stock-specific AI insight has been generated for ONCO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.88$270.00
$1.07
Fundamentals
Market Cap$3M
P/E Ratio0.0
EPS$1,377.40
Dividend Yield—
Dividend / Share—
ROE-123.3%
Profit Margin—
Debt / Equity—
Trading
Volume340K
Avg Volume (10D)—
Shares Outstanding3.7M
ONCO News
21 articles- Onconetix reverse split 10-to-1, aimed at Nasdaq $1 bid ruleStock Titan·May 19, 2026
- Onconetix, Inc. Announces 1-for-10 Reverse Stock SplitYahoo Finance·May 19, 2026
- Realbotix Provides Update on Nasdaq ListingYahoo Finance·May 19, 2026
- Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation StudyYahoo Finance·May 13, 2026
- Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and DevelopmentYahoo Finance·Apr 17, 2026
- Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to EricssonYahoo Finance·Apr 9, 2026
- Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I StrategyYahoo Finance·Apr 7, 2026
- Onconetix Highlights Realbotix AI Humanoid Robot Delivery UpdateYahoo Finance·Apr 2, 2026
- Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of DirectorsYahoo Finance·Mar 31, 2026
- BC-Most Active StocksYahoo Finance·Mar 27, 2026
- What's Going On With Onconetix Shares On Friday?Benzinga·Mar 27, 2026
- Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial DemonstrationYahoo Finance·Mar 25, 2026
- Onconetix, Inc. Announces 1-for-5 Reverse Stock SplitYahoo Finance·Mar 23, 2026
- Realbotix Announces the Sale of Realbotix, LLC Subsidiary to OnconetixYahoo Finance·Feb 12, 2026
- Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed IssuerYahoo Finance·Feb 12, 2026
- Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics CompanyYahoo Finance·Feb 12, 2026
- Onconetix announces financing through private placement, debt settlementYahoo Finance·Sep 27, 2025
- Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.Yahoo Finance·Sep 26, 2025
- Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger AgreementYahoo Finance·Sep 26, 2025
- Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTMYahoo Finance·Sep 22, 2025
- Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementYahoo Finance·Jul 16, 2025
All 21 articles loaded
Price Data
Open$0.92
Previous Close$0.95
Day High$1.07
Day Low$0.92
52 Week High$270.00
52 Week Low$0.88
52-Week Range
$0.88$270.00
$1.07
Fundamentals
Market Cap$3M
P/E Ratio0.0
EPS$1,377.40
Dividend Yield—
Dividend / Share—
ROE-123.3%
Profit Margin—
Debt / Equity—
Trading
Volume340K
Avg Volume (10D)—
Shares Outstanding3.7M
About Onconetix Inc
Onconetix Inc. is a pioneering biotechnology company dedicated to transforming cancer care through its innovative diagnostics and therapeutic solutions. Leveraging a proprietary technology platform, Onconetix focuses on early detection and personalized treatment strategies across various malignancies, addressing critical unmet needs in oncology. With a robust and diverse product pipeline, the company is strategically positioned to meet the growing demand for effective cancer therapies, significantly enhancing patient outcomes through its advanced research and development initiatives in this rapidly evolving field.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—